drugset / Trial / NCT00639158

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

NCT00639158

Phase 3 Completed 543 enrolled Abbott
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood.

Timeline

Start
2008-02
Primary completion
2008-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator ABT-335 Small molecule 135 mg
Comparator Atorvastatin Small molecule 40 mg
Comparator Ezetimibe Unknown 10 mg